Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
All outcomes

Feedback
 
Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchApilimodApilimod (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Outcomes in COVID-19 apilimod studies

0 0.5 1 1.5+ All studies -199% 1 141 Improvement, Studies, Patients Relative Risk Mortality -199% 1 141 RCTs -199% 1 141 Early -199% 1 141 Apilimod for COVID-19 c19early.org November 2025 Favorsapilimod Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -109% 2.09 [0.40-11.0] no recov. 4/64 2/67 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment -109% 2.09 [0.40-11.0] 4/64 2/67 109% higher risk All studies -109% 2.09 [0.40-11.0] 4/64 2/67 109% higher risk 1 apilimod COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Young (DB RCT) -100% 2.00 [0.19-21.6] death/hosp. 2/71 1/71 Young (DB RCT) -109% 2.09 [0.40-11.0] no recov. 4/64 2/67 Apilimod COVID-19 outcomes c19early.org November 2025 Favors apilimod Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit